Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/30/20
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal TumorsPRNewsWire • 07/24/20
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered CancersPRNewsWire • 07/14/20
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid CancersPRNewsWire • 07/01/20
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GISTPRNewsWire • 06/29/20
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic MastocytosisPRNewsWire • 06/06/20
Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/05/20
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal TumorPRNewsWire • 05/15/20
All You Need to Know About Blueprint Medicines (BPMC) Rating Upgrade to BuyZacks Investment Research • 05/14/20
How Blueprint Medicines (BPMC) Stock Stands Out in a Strong IndustryZacks Investment Research • 05/12/20
Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20